Nscale IPO filing masks ByteDance revenue reliance as U.S. export risks loom

Nscale IPO filing masks ByteDance revenue reliance as U.S. export risks loom
Nscale’s IPO faces risks

Nscale is pressing ahead with a New York listing after rapidly building its AI cloud business on demand for Nvidia chips outside China. The company’s filings show one customer generated 73 percent of last year’s revenue, highlighting concentration and regulatory risks tied to Chinese access to overseas computing power.

Highlights

  • Nscale's SEC filing reveals a single customer—identified by sources as ByteDance subsidiary Spring (SG) Pte Ltd—accounted for 73 percent of its $33 million 2025 revenue.
  • Nscale expanded its customer base with new multiyear computing agreements worth up to $44 billion with Microsoft and $45 billion with Anthropic, reducing ByteDance-related revenue to below 20 percent this year.
  • Nscale discloses over $2 billion in Nvidia commitments and an $860 million lease guarantee, but warns that tighter U.S. export controls on Chinese cloud customers could impact key accounts and pose reputational risks.

ByteDance link surfaces in IPO documents

As reported by Financial Times, Nscale’s main filing for a U.S. initial public offering does not name ByteDance directly, even though supporting documents and people familiar with the matter link the Chinese group to the unnamed customer that accounted for nearly three-quarters of 2025 revenue.

SEC paperwork says a single customer contributed 73 percent of Nscale’s $33 million in revenue last year. A loan agreement filed as an exhibit identifies Singapore entity Spring (SG) Pte Ltd as a significant customer, and people close to the company said Spring is a ByteDance subsidiary. The filings show Nscale signed a contract with Spring in May 2025 for 2,304 Nvidia B200 chips at the company’s data centre in Glomfjord, Norway.

The ByteDance agreement helped underpin a $105 million Macquarie loan, alongside $35 million in equity, to finance the purchase of those chips. The first tranche was drawn in August 2025, and the deal became an early commercial milestone for the London-based company soon after it split from its Australian bitcoin miner parent and launched its cloud push.

Nscale declines to comment. Macquarie declines to comment, while ByteDance and Nvidia do not respond to requests for comment in the source report.

Growth strategy brings geopolitical and disclosure pressure

Nscale has since expanded beyond that early customer base, signing much larger multiyear computing agreements worth up to $44 billion with Microsoft and $45 billion with Anthropic. It says revenue from its largest customer is set to fall below 20 percent this year as those U.S. contracts ramp up further.

The company also discloses growing backing from Nvidia, including more than $2 billion in commitments and a separate $860 million guarantee tied to lease obligations at a Texas facility. That support follows earlier backing from Nvidia chief executive Jensen Huang, who previously describes Nscale as a UK “national champion” as the company positions itself against neocloud rivals such as CoreWeave and Nebius.

Still, the ByteDance relationship underscores a sensitive business model used by some cloud providers, letting Chinese groups rent advanced AI computing abroad while U.S. export controls focus on direct chip sales. Nscale warns in its risk factors that tighter U.S. restrictions on Chinese entities’ cloud-based access to Nvidia chips could limit its ability to serve key customers, and that investors, partners and customers may see such dealings as a reputational risk.

Macquarie required monitoring of chip usage for possible export-control breaches, according to the filing, and people familiar with the matter say Nscale also carried out third-party due diligence on ByteDance and Spring. Lucian Bebchuk, a professor at Harvard Law School, says investors need visibility on both a company’s market and its risks, adding that a major Chinese customer is material to assessing an IPO candidate’s prospects.

Our earlier report on cross-border drug licensing with China explained how global pharmaceutical groups are increasingly licensing therapies and platforms from China’s biotech sector for overseas markets, with deal values rising sharply this year. It also noted that, despite intensifying U.S. policy pressure and new restrictions, China’s biotech industry remains broadly self-sufficient—leaving healthcare as a rare area where cross-border cooperation can still advance even as technology rivalry hardens.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.